New drug combo for first-line advanced pancreatic cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug (HRS-4642) combined with standard chemotherapy as a first treatment for advanced pancreatic cancer that has spread. It may help shrink tumors and extend life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have not had major surgery in the last 4 weeks.
- You do not have active hepatitis B or uncontrolled HIV.
- You have no serious heart or blood vessel problems in the last 6 months.
- You can take care of yourself (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug (HRS-4642) combined with nimotuzumab and chemotherapy for people with advanced pancreatic cancer that has a specific gene change called KRAS G12D. It's for those who haven't had treatment for advanced disease yet.
This trial tests a new drug combination for pancreatic cancer that has not been treated before. It may help shrink tumors or make surgery possible for people with advanced or borderline resectable disease.
This trial tests a new targeted drug (HRS-4642) combined with another drug (Nimotuzumab) and two chemotherapy drugs for people with a specific type of pancreatic cancer that has a KRAS G12D mutation. The goal is to see if this combination can help make the tumor smaller and possibly removable by surgery.
This trial tests whether combining two experimental drugs (GFH375 with GFS202A or GFH276) works better than one drug alone for people with advanced pancreatic cancer that has a specific genetic change called KRAS G12D. It may offer a new option for those who have already tried other treatments.
This trial tests a combination of two medications (HRS-4642 and AG) given before and after surgery for pancreatic cancer that can be removed. The goal is to see if this treatment helps prevent the cancer from coming back.
This trial tests a new drug, HRS-4642, combined with other cancer treatments for people with advanced solid tumors. It looks at how well the combination works and if it is safe for you.
Hear when a new KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.